2.1 MyD88 as a potential therapeutic target for tangling severe inflammation and augmenting antiviral type I IFN response with SARS-CoV-2 (COVID-19) infection: a proposition for post-exposure therapy against COVID-19. Here, MYD88 is linked to COVID-19.